Tularik
7
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
28.6%
2 terminated/withdrawn out of 7 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Role: lead
T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy
Role: lead
Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.
Role: lead
Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus
Role: lead
Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.
Role: lead
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Role: lead
Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.
Role: lead
All 7 trials loaded